The most can­did man in phar­ma strikes again.

When asked on Tues­day’s earn­ings call whether Pfiz­er would con­sid­er a “trans­for­ma­tive M&A” deal in the near...

BioN­Tech is mak­ing big cuts to its man­u­fac­tur­ing foot­print.

The Ger­man com­pa­ny said in its first-quar­ter earn­ings re­leasethat up to 1,860 man­u­fac­tur­ing staff could...

In­ter­cept Phar­ma­ceu­ti­cal­s' at­tempt at cre­at­ing a next-gen­er­a­tion FXR ag­o­nist for cer­tain forms of liv­er in­flam­ma­tion ap­pears to have end­ed.

The drug de­vel­op­er's INT-787 showed "no...

Pfiz­er has dis­con­tin­ued the fi­nal clin­i­cal study stem­ming from its 2021 ac­qui­si­tion of Tril­li­um Ther­a­peu­tics, fun­nel­ing cash pri­mar­i­ly to­ward a host of oth­er can­cer and...

Madri­gal Phar­ma­ceu­ti­cals has made its fourth MASH deal in 10 months, fur­ther sig­nal­ing its am­bi­tions to be not just the first drug­mak­er for the fat­ty...

Cy­to­ki­net­ics&